tale expect
post beat rais quarter expect print high
share sold investor question qualiti guidanc rais
convers introduc below-street guidanc serv clear
event net-net compani earn suggest stabl fundament
view decis exit pharmedium busi focu core asset
favor financi strateg remov distract
weigh manag time rais price target
key highlight compani decemb earn
debat post abc print whether updat guidanc reflect manag
confid sustain improv brand gener trend
guidanc impli pharmaceut distribut segment growth
remaind year
analysi suggest updat guidanc adjust pharmedium
exit impli wide rang pharma segment ebit growth
see exhibit reflect combin difficult y/i comp fact
still earli fiscal year like limit visibl price
updat estim increas price target
updat forecast reflect updat guidanc model
ep within guidanc rang updat dcf-
base price target impli ebitda
exclud opioid liabil multipl slightli
averag multipl abc share
guidanc impact higher invest come relief
guidanc came consensu vs ms outlook
weigh strateg invest recent blueprint genet
acquisit liquid biopsy/next gener sequenc autom
headwind includ street estim
share gain continu guidanc call revenu
growth expect continu share gain in-network
relationship payor bcb new jersey
georgia well inclus unit prefer lab network pln unit
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
increas focu get physician use pln via reimburs
incent support potenti share gain opportun remain key swing
factor earn target
price environ challeng lead time take longer
suggest limit upsid newli establish guid manag
reiter strong pipelin deal consist prior commentari
note deal take time close due complex natur
larger hospit system discuss moreov price
environ continu challeng combin headwind
offset benefit invigor cost cut plan previous expect
accret bottom line earn cross walk exhibit
updat estim increas price target
updat model reflect new guidanc model ep
updat price target repres year
forward pe discount current pe multipl in-lin
late januari decid exit pharmedium busi background
recogn million impair charg expect recogn
million impair connect pharmedium compani also
expect recogn cash tax benefit fiscal fiscal total
estim pharma ebit grew y/i enterpris ebit grew
normal pharmedium loss million
exhibit ebit result adjust pharmedium impact
pharmedium adjust impact ebit
exhibit ebit adjust pharmedium impact
pharmedium adjust impact ebit
normal ebit impli guid
exhibit second half ebit adjust pharmedium impact
pharmedium adjust impact ebit
normal ebit impli guid
exhibit ep crosswalk
ep tailwind
invest pay benefit
bear bull midpoint vs ms
con guidanc
morgan stanley estim compani data
exhibit ebit crosswalk
ebita tailwind
invest pay benefit
morgan stanley estim compani data
exhibit top-line breakdown
base management commentari non-access growth bp
base ms estimate bp benefit blueprint genet full year bp benefit
memori hermann start
base mgmt/ commentari slightli greater bp reimburs pressur
estim bp posit leap day bp benefit full year
morgan stanley estim compani data
market leader specialti balanc risk-reward
wacc addit assum global opioid litig settlement
estim respons
second largest
drug wholesal us largest
specialti distributor posit benet
grow specialti pipelin
among distributor
highest revenu exposur higher-growth
higher-margin specialti
opioid liabil continu
distribut agreement
walgreen largest custom provid
compani long term revenu
visibl sourc benet
greater scrutini brand inat
pharmedium limit new product
introduct like continu weigh
growth prole forseeabl futur
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
ebitda excl opioid
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
ebitda excl opioid
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
ebitda excl opioid
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
drug price increas particularli januari
gener manufactur commentari gener
news ow opioid litig settlement
increas brand inat
acceler growth specialti drug
distribut servic
signic slowdown brand inat
deterior gener price deation
continu price pressur margin eros
increas opioid legal settlement payment
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
nt/lt share gain opp open payor contract market consolid
price-to-earnings base case ep multipl reect discount current
multipl averag year discount
largest nation
lab market share physician lab
unit decis open lab contract
establish long-term strateg
partnership two nation lab
labcorp set
stage ration price provid quest
opportun gain market share
capit deploy form tuck-in
strategi cost cut program
invigor increas test mix toward
advanc molecular diagnost
view descript risk reward theme
price-to-earnings bull case ep
bull case multipl reect premium
bull case multipl reect premium
current multipl
current multipl in-lin
price-to-earnings base case ep
base case multipl reect discount
base case multipl reect discount
current multipl
current multipl in-lin
price-to-earnings bear case ep
bear case multipl reect discount
bear case multipl reect discount
current multipl
current multipl in-lin
volum growth move in-network
bcbsnj less scale region
player well prefer lab
view explan region hierarchi
research highest favor quintil
quest diagnost inc earn guidanc
higher core volum growth faster
expect share gain region
revers pama cut
consolid driver higher benet
volum growth share gain meet
save program magnitud come
expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
